title: Paclitaxel disrupts polarized entry of membrane-permeable C6 ceramide into ovarian cancer cells resulting in synchronous induction of cell death.
abstract: Exogenous cell-permeable C6 ceramide has been demonstrated to act synergistically with chemotherapeutic drugs, including paclitaxel, cisplatin, doxorubicin and the histone deacetylase inhibitor, trichostatin A, to induce cell death in a variety of cancer cells. We previously demonstrated that C6 ceramide and paclitaxel function synergistically to induce ovarian cancer cell death via modulation of the PI3/AKT cell survival pathway. In the present study, the entry pattern of C6 ceramide into ovarian cancer cells was investigated using fluorescent short chain C6-NBD sphingomyelin (C6-NBD). Confocal microscopy revealed that C6-NBD enters the cells in a polarized pattern, characterized by marked signals at one cellular end, representing a likely mitosis initiation site. Pretreatment of the cells with filipin, an inhibitor of the lipid raft/caveolae endocytosis pathway, decreases C6-NBD entry into the cells. A pretreatment with the water channel inhibitor, CuSO4, was also found to reduce the entry of C6-NBD. Notably, the pretreatment with paclitaxel was shown to disrupt the polarized entry of C6-NBD into the cells, resulting in an even distribution of C6-NBD in the cytoplasm. In addition, the pretreatment of the cells with paclitaxel destabilized the cytoskeletal proteins, releasing an increased number of short tubulin fragments. The results of the present study indicate that C6 ceramide preferentially enters the cells via a predetermined initiation site of mitosis. In addition to diffusion, short chain C6 ceramide may also enter cells via water channels and caveolae-mediated endocytosis. Paclitaxel disrupts the cell cytoskeleton and induces an even distribution of C6 ceramide in the cytoplasm resulting in synergistic ovarian cancer cell death.
authors.affiliation: Department of Biology, Providence College, Providence, RI 02918, USA ;
authors.forename: Charles
authors.initials: C
authors.lastname: Best
authors.forename: David
authors.initials: D
authors.lastname: Calianese
authors.forename: Kevin
authors.initials: K
authors.lastname: Szulak
authors.forename: Garret
authors.initials: G
authors.lastname: Cammarata
authors.forename: Gabriella
authors.initials: G
authors.lastname: Brum
authors.forename: Thomas
authors.initials: T
authors.lastname: Carbone
authors.forename: Eric
authors.initials: E
authors.lastname: Still
authors.forename: Katelyn
authors.initials: K
authors.lastname: Higgins
authors.forename: Fang
authors.initials: F
authors.lastname: Ji
authors.forename: Wen
authors.initials: W
authors.lastname: DI
authors.forename: Harold
authors.initials: H
authors.lastname: Wanebo
authors.forename: Yinsheng
authors.initials: Y
authors.lastname: Wan
keywords: AKT; C6 ceramide; ovarian cancer; paclitaxel